291 related articles for article (PubMed ID: 38250812)
1. Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.
Feng Y; Huo Q; Li BY; Yokota H
Proteomes; 2023 Dec; 12(1):. PubMed ID: 38250812
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer-associated urinary proteomes differ before and after prostatectomy.
Feng Y; Liu S; Zha R; Sun X; Li K; Wu D; Aryal UK; Koch M; Li BY; Yokota H
Ther Adv Med Oncol; 2022; 14():17588359221131532. PubMed ID: 36324734
[TBL] [Abstract][Full Text] [Related]
3. The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs).
Li K; Huo Q; Li BY; Yokota H
Proteomes; 2023 Jan; 11(1):. PubMed ID: 36810561
[TBL] [Abstract][Full Text] [Related]
4. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling.
Sun X; Li K; Hase M; Zha R; Feng Y; Li BY; Yokota H
Theranostics; 2022; 12(2):929-943. PubMed ID: 34976221
[No Abstract] [Full Text] [Related]
5. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
6. Validation of potential RNA biomarkers for prostate cancer diagnosis and monitoring in plasma and urinary extracellular vesicles.
Brokāne A; Bajo-Santos C; Zayakin P; Belovs A; Jansons J; Lietuvietis V; Martens-Uzunova ES; Jenster GW; Linē A
Front Mol Biosci; 2023; 10():1279854. PubMed ID: 38099195
[No Abstract] [Full Text] [Related]
7. Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes.
Li K; Sun X; Li H; Ma H; Zhou M; Minami K; Tamari K; Ogawa K; Pandya PH; Saadatzadeh MR; Kacena MA; Pollok KE; Li BY; Yokota H
Genes Dis; 2023 Jul; 10(4):1641-1656. PubMed ID: 37397541
[TBL] [Abstract][Full Text] [Related]
8. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.
Pandha H; Sorensen KD; Orntoft TF; Langley S; Hoyer S; Borre M; Morgan R
BJU Int; 2012 Sep; 110(6 Pt B):E287-92. PubMed ID: 22583908
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Three unconventional maxims in the natural selection of cancer cells: Generation of induced tumor-suppressing cells (iTSCs).
Li K; Huo Q; Li BY; Yokota H
Int J Biol Sci; 2023; 19(5):1403-1412. PubMed ID: 37056934
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic analysis of dysregulated proteins in prostate cancer patients reveals putative urinary biomarkers and key biological pathways.
Lima T; Henrique R; Vitorino R; Fardilha M
Med Oncol; 2021 Jan; 38(1):9. PubMed ID: 33452612
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
13. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
[TBL] [Abstract][Full Text] [Related]
14. Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.
Jedinak A; Loughlin KR; Moses MA
Oncotarget; 2018 Aug; 9(65):32534-32550. PubMed ID: 30197761
[TBL] [Abstract][Full Text] [Related]
15. Urinary biomarkers of prostate cancer.
Fujita K; Nonomura N
Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of urinary tract infections and urinary antibodies after radical prostatectomy and cystoprostatectomy.
Iwakiri J; Freiha FS; Shortliffe LM
Urol Clin North Am; 2002 Feb; 29(1):251-8, xii. PubMed ID: 12109353
[TBL] [Abstract][Full Text] [Related]
17. Urinary markers for prostate cancer.
Downes MR; Byrne JC; Pennington SR; Dunn MJ; Fitzpatrick JM; Watson RW
BJU Int; 2007 Feb; 99(2):263-8. PubMed ID: 17092277
[TBL] [Abstract][Full Text] [Related]
18. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
19. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
[TBL] [Abstract][Full Text] [Related]
20. Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation.
Nyren-Erickson EK; Bouton M; Raval M; Totzauer J; Mallik S; Alberto N
J Negat Results Biomed; 2014 Apr; 13():5. PubMed ID: 24690292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
